Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of PXS-5382A in Healthy Males
NCT04183517Phase 1Completed
- Sponsor
- Syntara Limited
- Start
- Dec 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PXS-5382A in Nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), kidney fibrosis and 1 more (3 arms), sponsored by Syntara Limited. Primary endpoints: Maximum Plasma Concentration at 6 days, Time to Maximum Plasma Concentration at 6 days and 2 more. Started Dec 2019; status: completed.
02
Drugs
PXS-5382A
03
Conditions
Nonalcoholic steatohepatitis (NASH)idiopathic pulmonary fibrosis (IPF)kidney fibrosisheart failure (HF)
Beyond the preview
Go deeper on NCT04183517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183517.